Featured 13F manager
DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $524M
- 88 Positions
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
Nathan Fischel files DAFNA Capital Management LLC as a Form 13F. The latest book is 2026 Q2 at $524M, up 19.1% QoQ, led by Revolution Medicines, Spdr S&P Biotech ETF, and Compass Pathways.
Portfolio
top 5 40.2% · top 10 56.2%
- RVMD - Revolution Medicines 20.1%
- XBI - Spdr S&P Biotech ETF 5.9%
- CMPS - Compass Pathways 5.4%
- STXS - Stereotaxis 4.5%
- NKTR - Nektar Therapeutics 4.3%
- DNLI - Denali Therapeutics 3.6%
- IDYA - Ideaya Biosciences 3.5%
- ATRC - Atricure 3.2%
- XENE - Xenon Pharmaceuticals 2.9%
- CYTK - Cytokinetics 2.8%
- RCUS - Arcus Biosciences 2.6%
- ASND - Ascendis Pharma A/S 2.5%
- Other 38.7%
AUM over time
Latest book
| RVMD - Revolution Medicines | 20.09% | Reduce −3.1% | 562,630 | $187.28 | $105M | −18,048 | +$49M |
| XBI - Spdr S&P Biotech ETF | 5.93% | Reduce −38.3% | 196,505 | $158.25 | $31M | −122,000 | −$10M |
| CMPS - Compass Pathways | 5.43% | Reduce −16.8% | 2,011,952 | $14.15 | $28M | −406,930 | +$15M |
| STXS - Stereotaxis | 4.49% | Hold | 13,680,554 | $1.72 | $24M | — | — |
| NKTR - Nektar Therapeutics | 4.24% | Add +92.7% | 318,380 | $69.81 | $22M | +153,202 | +$10M |
| DNLI - Denali Therapeutics | 3.62% | Add +132.0% | 739,014 | $25.72 | $19M | +420,514 | +$13M |
| IDYA - Ideaya Biosciences | 3.53% | Add +4.3% | 497,240 | $37.27 | $19M | +20,500 | +$3M |
| ATRC - Atricure | 3.19% | Hold | 597,431 | $27.98 | $17M | — | — |
| XENE - Xenon Pharmaceuticals | 2.89% | Hold | 250,772 | $60.36 | $15M | — | — |
| CYTK - Cytokinetics | 2.79% | Reduce −20.9% | 171,998 | $85.19 | $15M | −45,499 | +$317K |
| RCUS - Arcus Biosciences | 2.60% | Reduce −0.5% | 441,829 | $30.83 | $14M | −2,000 | +$4M |
| ASND - Ascendis Pharma A/S | 2.47% | New | 48,469 | $266.72 | $13M | +48,469 | +$13M |
| NBIX - Neurocrine Biosciences | 1.86% | Reduce −18.2% | 57,769 | $168.53 | $10M | −12,846 | +$433K |
| AXGN - Axogen | 1.84% | Reduce −16.4% | 208,960 | $46.19 | $10M | −41,000 | +$1M |
| PODD - Insulet | 1.80% | Add +469.2% | 61,870 | $152.25 | $9M | +51,000 | +$7M |
| EWTX - Edgewise Therapeutics | 1.76% | Add +102.1% | 226,819 | $40.63 | $9M | +114,583 | +$6M |
| BCAX - Bicara Therapeutics | 1.61% | Reduce −32.4% | 284,955 | $29.69 | $8M | −136,778 | +$72K |
| NDAQ - Ishares Nasdaq Biotech Indx | 1.54% | Reduce −31.4% | 42,595 | $190.19 | $8M | −19,500 | −$2M |
| SNDX - Syndax Pharmaceuticals | 1.40% | Add +54.2% | 335,255 | $21.86 | $7M | +117,900 | +$2M |
| MPLT - Maplight Therapeutics | 1.17% | Hold | 171,006 | $35.84 | $6M | — | — |
| LRMR - Larimar Therapeutics | 1.17% | Reduce −1.0% | 2,008,164 | $3.05 | $6M | −21,000 | −$3M |
| IPSC - Century Therapeutics | 1.12% | Reduce −1.4% | 2,400,458 | $2.45 | $6M | −33,895 | +$379K |
| DXCM - Dexcom | 1.11% | Hold | 86,279 | $67.35 | $6M | — | — |
| IMVT - Immunovant | 1.10% | Reduce −0.7% | 149,524 | $38.53 | $6M | −1,000 | +$2M |
| INGN - Inogen | 1.04% | Hold | 845,179 | $6.45 | $5M | — | — |
| TNDM - Tandem Diabetes Care | 1.02% | Hold | 355,208 | $15.09 | $5M | — | — |
| ALKS - Alkermes | 1.01% | Reduce −27.4% | 101,266 | $52.39 | $5M | −38,216 | +$374K |
| STOK - Stoke Therapeutics | 0.82% | Hold | 130,875 | $32.72 | $4M | — | — |
| ALLO - Allogene Therapeutics | 0.79% | Add +46.0% | 2,000,000 | $2.08 | $4M | +629,882 | +$817K |
| BCRX - Biocryst Pharmaceuticals | 0.76% | Reduce −7.0% | 400,248 | $10.00 | $4M | −30,000 | −$93K |
| LKFT - Lakefront Biotherapeutics | 0.74% | Hold | 130,175 | $29.98 | $4M | — | — |
| KIDS - Orthopediatrics | 0.69% | Add +97.7% | 189,130 | $19.13 | $4M | +93,471 | +$2M |
| CYBN - Cybin | 0.65% | Add +3.2% | 514,061 | $6.61 | $3M | +15,700 | +$1M |
| RAPP - Rapport Therapeutics | 0.60% | Hold | 75,000 | $41.67 | $3M | — | — |
| KYMR - Kymera Therapeutics | 0.59% | New | 27,000 | $114.67 | $3M | +27,000 | +$3M |
| PRQR - Proqr Therapeutics | 0.54% | Reduce −2.4% | 1,530,361 | $1.86 | $3M | −37,200 | +$307K |
| NGNE - Neurogene | 0.53% | Add +57.2% | 89,032 | $31.45 | $3M | +32,397 | +$2M |
| ANL - Adlai Nortye | 0.53% | New | 239,553 | $11.50 | $3M | +239,553 | +$3M |
| PRCT - Procept Biorobotics | 0.52% | Hold | 120,000 | $22.58 | $3M | — | — |
| AQST - Aquestive Therapeutics | 0.51% | Add +75.3% | 645,915 | $4.16 | $3M | +277,500 | +$1M |
| CLDX - Celldex Therapeutics | 0.49% | Hold | 68,518 | $37.21 | $3M | — | — |
| GPCR - Structure Therapeutics | 0.48% | Hold | 46,500 | $53.67 | $2M | — | — |
| ALGN - Align Technology | 0.45% | Reduce −6.7% | 14,000 | $168.66 | $2M | −1,000 | −$210K |
| VKTX - Viking Therapeutics | 0.44% | Hold | 59,516 | $39.01 | $2M | — | — |
| NGEN - Nervgen Pharma | 0.41% | New | 1,050,000 | $2.06 | $2M | +1,050,000 | +$2M |
| BHVN - Biohaven | 0.39% | Reduce −83.7% | 137,593 | $14.88 | $2M | −708,142 | −$5M |
| MAZE - Maze Therapeutics | 0.37% | Add +85.7% | 65,000 | $29.84 | $2M | +30,000 | +$895K |
| ALEC - Alector | 0.35% | Hold | 908,351 | $2.01 | $2M | — | — |
| LXEO - Lexeo Therapeutics | 0.33% | Hold | 377,059 | $4.66 | $2M | — | — |
| PROF - Profound Medical | 0.33% | Reduce −1.0% | 260,360 | $6.65 | $2M | −2,645 | +$27K |
| RNA - Atrium Therapeutics | 0.33% | New | 128,000 | $13.45 | $2M | +128,000 | +$2M |
| ANNX - Annexon | 0.32% | Add +152.8% | 297,812 | $5.71 | $2M | +180,000 | +$1M |
| CTMX - Cytomx Therapeutics | 0.31% | Add +90.6% | 438,407 | $3.75 | $2M | +208,407 | +$563K |
| RARE - Ultragenyx Pharmaceutical | 0.30% | Reduce −22.9% | 47,100 | $33.39 | $2M | −14,000 | +$293K |
| Eupraxia Pharmaceuticals | 0.28% | New | 225,600 | $6.61 | $1M | +225,600 | +$1M |
| DSGN - Design Therapeutics | 0.28% | New | 102,600 | $14.47 | $1M | +102,600 | +$1M |
| FATE - Fate Therapeutics | 0.27% | Reduce −4.5% | 525,000 | $2.70 | $1M | −25,000 | +$758K |
| Mediwound | 0.26% | Hold | 94,405 | $14.70 | $1M | — | — |
| KURA - Kura Oncology | 0.25% | Reduce −48.9% | 120,568 | $10.97 | $1M | −115,300 | −$595K |
| SPRY - Ars Pharmaceuticals | 0.25% | Add +17.9% | 164,285 | $8.01 | $1M | +25,000 | +$197K |
| MLYS - Mineralys Therapeutics | 0.23% | Add +15.6% | 44,490 | $26.98 | $1M | +6,000 | +$158K |
| Immatics | 0.23% | Reduce −48.2% | 116,960 | $10.13 | $1M | −108,900 | −$1M |
| TELA - Tela Bio | 0.21% | Hold | 1,441,029 | $0.7500 | $1M | — | — |
| Polypid | 0.20% | Hold | 207,900 | $5.08 | $1M | — | — |
| CRBP — | 0.19% | New | 107,773 | $9.38 | $1M | +107,773 | +$1M |
| INSP - Inspire Medical Systems | 0.15% | Hold | 18,200 | $44.61 | $812K | — | — |
| ACET - Adicet Bio | 0.15% | Hold | 93,812 | $8.64 | $811K | — | — |
| SEG - Seaport | 0.13% | New | 32,400 | $21.72 | $704K | +32,400 | +$704K |
| MBX - Mbx Biosciences | 0.12% | Reduce −93.3% | 11,809 | $55.20 | $652K | −163,656 | −$5M |
| BNTX - Biontech Se | 0.12% | Hold | 7,000 | $93.05 | $651K | — | — |
| ARTV - Artiva Biotherapeutics | 0.12% | New | 67,101 | $9.70 | $651K | +67,101 | +$651K |
| PLRX - Pliant Therapeutics | 0.11% | Hold | 487,000 | $1.14 | $555K | — | — |
| Scynexis | 0.11% | New | 135,868 | $4.07 | $553K | +135,868 | +$553K |
| EDIT - Editas Medicine | 0.11% | New | 170,470 | $3.24 | $552K | +170,470 | +$552K |
| OBIO - Orchestra Biomed | 0.10% | Hold | 126,841 | $4.32 | $547K | — | — |
| FHTX - Foghorn Therapeutics | 0.10% | Hold | 111,859 | $4.88 | $546K | — | — |
| ARAY - Accuray | 0.08% | Hold | 1,680,508 | $0.2578 | $433K | — | — |
| QTTB - Q32 Bio | 0.08% | New | 32,896 | $12.74 | $419K | +32,896 | +$419K |
| Nuvectis Pharma | 0.07% | New | 20,000 | $18.39 | $368K | +20,000 | +$368K |
| Compugen | 0.07% | Reduce −34.7% | 168,232 | $2.14 | $360K | −89,551 | −$189K |
| IBIO — | 0.06% | Reduce −12.2% | 170,053 | $1.75 | $298K | −23,585 | −$70K |
| AUTL - Autolus Therapeutics | 0.05% | Hold | 179,316 | $1.60 | $287K | — | — |
| BCYC - Bicycle Therapeutics | 0.05% | Hold | 64,492 | $4.24 | $273K | — | — |
| Tenaya Therapeutics | 0.04% | New | 300,000 | $0.7391 | $222K | +300,000 | +$222K |
| VRCA - Verrica Pharmaceuticals | 0.03% | Reduce −84.5% | 23,750 | $6.12 | $145K | −129,962 | −$668K |
| Engene Therapeutics | 0.02% | New | 74,650 | $1.73 | $129K | +74,650 | +$129K |
| Kardigan | 0.02% | New | 5,000 | $23.85 | $119K | +5,000 | +$119K |
| ADCT - Adc Therapeutics SA | 0.02% | Add +6.9% | 77,081 | $1.07 | $82K | +5,000 | −$188K |
Showing top 50 of 88 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2026 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| DAWNGBX — | 4.77% | Exit | 0 | $21.44 | $21M | −978,463 | −$21M |
| Kalvista Pharmaceuticals | 1.22% | Exit | 0 | $20.13 | $5M | −267,402 | −$5M |
| ASND - Ascendis Pharma A/S | 1.21% | Exit | 0 | $228.72 | $5M | −23,177 | −$5M |
| FULC - Fulcrum Therapeutics | 0.36% | Exit | 0 | $7.67 | $2M | −205,000 | −$2M |
| Engene | 0.29% | Exit | 0 | $6.81 | $1M | −187,353 | −$1M |
| SCYXEUR - Scynexis | 0.23% | Exit | 0 | $0.9172 | $997K | −1,086,956 | −$997K |
| ORIC - Oric Pharmaceuticals | 0.22% | Exit | 0 | $9.57 | $945K | −98,724 | −$945K |
| ZBIO - Zenas Biopharma | 0.19% | Exit | 0 | $19.55 | $831K | −42,500 | −$831K |
| NAMS - Newamsterdam Pharma | 0.15% | Exit | 0 | $32.00 | $640K | −20,000 | −$640K |
| KPTI - Karyopharm Therapeutics | 0.06% | Exit | 0 | $5.57 | $255K | −45,800 | −$255K |
| NMRA - Neumora Therapeutics | 0.03% | Exit | 0 | $1.96 | $137K | −70,000 | −$137K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site · 2021 Q3–2026 Q2